Related Experiment Video
Updated: Jun 20, 2026
08:43
Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase (G6PI)-Induced RA Mice
Published on: January 31, 2020
IRAK-4 inhibitors for inflammation
Zhulun Wang1, Holger Wesche, Tracey Stevens
1Amgen Inc, South San Francisco, CA 94080, USA. zwang@amgen.com
Current Topics in Medicinal Chemistry
|August 20, 2009
Summary
Interleukin-1 receptor-associated kinase 4 (IRAK-4) is crucial for immune signaling. Inhibiting its kinase activity offers a promising strategy for developing new anti-inflammatory therapies to combat immune and inflammatory diseases.
Area of Science:
- Immunology
- Molecular Biology
- Pharmacology
Background:
- Interleukin-1 receptor-associated kinases (IRAKs) mediate signaling for IL-1R, IL-18R, and TLRs.
- IRAK-4 is the essential IRAK for IL-1R/TLR signaling, and its deficiency causes susceptibility to bacterial infections.
- IRAK-4 kinase activity is vital for its function, making it a therapeutic target.
Purpose of the Study:
- To review the biological function and structural characteristics of IRAK-4.
- To discuss the development of small molecule inhibitors targeting IRAK-4 kinase activity.
- To summarize strategies for developing IRAK-4 inhibitors as anti-inflammatory agents.
Main Methods:
- Review of existing literature on IRAK-4 biology and inhibitor development.
- Analysis of structural data for IRAK-4 kinase domain in complex with inhibitors.
- Identification of key pharmacophores and protein-inhibitor interactions.
Main Results:
- IRAK-4 plays a central role in inflammatory and immune responses.
- Structural insights have enabled the design of specific IRAK-4 kinase inhibitors.
- Understanding of IRAK-4 function facilitates the development of novel therapeutic strategies.
Conclusions:
- Targeting IRAK-4 kinase activity is a viable therapeutic approach for immune and inflammatory diseases.
- Structure-based drug design is crucial for developing potent and specific IRAK-4 inhibitors.
- Further research can lead to new anti-inflammatory agents based on IRAK-4 inhibition.
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...